体积指血采样监测肾移植受者他克莫司、肌酐和血红蛋白的临床性能
该研究在肾移植受者中验证两种体积指血采样装置(Capitainer qDBS和Mitra)监测他克莫司、肌酐和血红蛋白的临床性能,并比较医护人员采样与自我采样及两种装置的差异。结果显示两种装置技术可行,Capitainer在自我采样中保持稳定的采样成功率和分析质量,可能简化肾移植受者随访。
要点
- Capitainer和Mitra用于监测他克莫司、肌酐和血红蛋白技术可行。
- Capitainer在自我采样中采样成功率稳定(92%-96%)。
- 实施体积指血自我采样可能简化和改善肾移植受者随访。
核心结论
- Capitainer和Mitra两种体积指血采样装置用于测量他克莫司、肌酐和血红蛋白技术可行。
- 在自我采样情境下,Capitainer保持一致的采样成功率和分析质量。
- 实施体积指血自我采样监测他克莫司、肌酐和血红蛋白可能简化和改善肾移植受者随访。
研究设计与样本
- 研究比较指血采样与静脉采血,涵盖三种情境:医护人员微量采样、监督下自我采样、无监督自我采样。
- 指血样本用适配方法分析,结果与静脉血样本的常规方法分析比较。
主要发现
- 他克莫司测量值和预测AUC的差异在±20%以内的比例:Capitainer为79%-96%,Mitra为77%-95%。
- 肌酐差异在±15%以内的比例:Capitainer为92%-100%,Mitra为79%-96%。
- 血红蛋白差异在±15%以内的比例:Capitainer为93%-100%,Mitra为67%-92%。
- 采样成功率:Capitainer一致为92%-96%;Mitra在医护人员采样时为72%-88%,患者自我采样时为52%-72%。
临床怎么用
- 可考虑使用Capitainer或Mitra体积指血采样装置监测肾移植受者的他克莫司、肌酐和血红蛋白。
- 在自我采样场景下,Capitainer的采样成功率和分析质量更稳定。
- 体积指血自我采样可能简化并改善肾移植受者的随访流程。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: Finger-prick sampling has emerged as an attractive tool for therapeutic drug monitoring and associated diagnostics. We aimed to validate the clinical performance of using two volumetric devices (Capitainer® qDBS and Mitra®) for monitoring tacrolimus, creatinine and haemoglobin in kidney transplant (KTx) recipients. Secondarily, we evaluated potential differences between finger-prick sampling performed by healthcare professionals vs. self-sampling, and differences between the two devices. METHODS: We compared finger-prick and venous sampling in three settings: microsampling performed by healthcare personnel, self-sampling under supervision, unsupervised self-sampling. The finger-prick samples were analysed with adapted methods and results compared to routine method analysis of the venous blood samples. RESULTS: Twenty-five KTx recipients completed the main study and 12 KTx recipients completed a post hoc validation study. For tacrolimus measurements and predicted area under the curve, the proportions within ±20% difference were 79%-96% for Capitainer and 77%-95% for Mitra. For creatinine and haemoglobin, the proportions within ±15% were 92%-100% and 93%-100% for Capitainer and 79%-96% and 67%-92% for Mitra, respectively. Comparing sampling situations, the success rate was consistent for Capitainer (92%-96%), whereas Mitra showed 72%-88% and 52%-72% success rates with samples collected by healthcare personnel and the patients themselves. CONCLUSIONS: Capitainer and Mitra are technically feasible for measuring tacrolimus, creatinine and haemoglobin. In the context of self-sampling, Capitainer maintained consistent sampling success and analytical quality. Implementing volumetric finger-prick self-sampling for the monitoring of tacrolimus, creatinine and haemoglobin may simplify and improve the follow-up of KTx recipients.
引用
- Vethe NT, Åsberg A, Andersen AM, et al. Clinical performance of volumetric finger-prick sampling for the monitoring of tacrolimus, creatinine and haemoglobin in kidney transplant recipients. Br J Clin Pharmacol. 2023. PMID: 37537150. doi:10.1111/bcp.15870
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。